Live Demo: auto mode for HAP
This page describes a typical case of Hospital-Acquired Pneumonia (HAP).
Key bacteria include Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus.
According to current guidelines, the calculated initial therapy depends on the patient's risk factors. For patients with an increased risk of multi-resistant pathogens (MRE), a broad-spectrum antibiotic such as Piperacillin/Tazobactam is recommended. For patients without MRE risk factors, broad-spectrum Cephalosporins are often used.
The table below is generated by scanning the text on this page.
| Staphylococcus aureus | Klebsiella pneumoniae | Pseudomonas aeruginosa | |
|---|---|---|---|
| Piperacillin | — | — | 17.4% |
| Piperacillin/Tazobactam | 7.2% | 15.3% | 13.9% |
| Cefazolin | — | — | R |
| Cefuroxime | 6.7% | 15.4% | R |
| Cefoxitin | 7.5% | — | R |
| Ceftriaxone | 7.6% | 10.1% | R |
| Cefotaxime | 7.7% | 10.6% | R |
| Ceftazidime | R | 10.9% | 9.6% |
| Cefepime | 6% | 10.7% | 8.7% |
4 antibiotics hidden (show)
Sources: EUCAST: Intrinsic Resistance and Expert Rules, Antibiotic Resistance Surveillance (ARS), Germany (All Data), 2023